Cannabist Co Holdings Inc 8-K, filed Mar 29, 2023
Cannabist Co Holdings Inc. (CBSTQ)
About this 8-K
Cannabist Co Holdings Inc filed this 8-K on March 29, 2023.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) | |||
(
(Registrant’s telephone number, including area code)
Not Applicable
(Registrant’s name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.
| Item 2.02. | Results of Operations and Financial Condition. |
On March 29, 2023, Columbia Care Inc., a British Columbia corporation (“Columbia Care”), issued a press release announcing financial results for the quarter and year ended December 31, 2022 and provided an investor presentation to accompany the press release. Copies of the press release and investor presentation are being furnished as Exhibits 99.1 and 99.2, respectively, to this Form 8-K, which are incorporated into this item by reference.
The information furnished under this Item 2.02 and in the accompanying Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated March 29, 2023 | |
| 99.2 | Investor Presentation, dated March 29, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COLUMBIA CARE INC. | ||
| By: | /s/ Nicholas Vita | |
| Name: | Nicholas Vita | |
| Title: | Chief Executive Officer | |
Date: March 29, 2023
Exhibit 99.1
Columbia Care Reports Fourth Quarter and Full Year 2022 Results
Record Annual Revenue of $511.6 Million, an Increase of 11% YoY
Record Annual Gross Profit of $201.2 Million, an increase of 4% YoY
Record Annual Adjusted EBITDA1 of $67.4 Million, an Increase of 17% YoY
and Annual Adjusted EBITDA Margin1 of 13%, an Increase of 60bps YoY
NEW YORK, N.Y., March 29, 2023 – Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today reported its financial and operating results for the fourth quarter and full year ended December 31, 2022. All financial information presented in this release is in U.S. GAAP and in thousands of U.S. dollars, unless otherwise noted.
“Columbia Care achieved record financial results again in 2022, as we continued to build scale and optimize our portfolio of assets within our strategically diverse retail footprint. Despite cyclicality in the fourth quarter coinciding with ongoing macroeconomic headwinds that impacted both the consumer, and in particular, wholesale market pricing, topline revenue grew to more than $511 million, up 11% over 2021, and we improved our Adjusted EBITDA margin by 60 basis points during that same time period. Our strategic position in the fastest growing markets in the country continues to drive revenue and earnings growth, as we see an increasing contribution from markets such as New Jersey and Virginia,” said Nicholas Vita, CEO of Columbia Care.
Vita continued, “We are focusing our footprint on those markets that can drive the most value for our patients, customers, and shareholders – and reducing exposure in markets that do not contribute to the bottom line. The ongoing operational and financial reprioritization of resources we began implementing in the fourth quarter of 2022, which included a targeted corporate restructuring, multiple cost-reduction measures, several non-core asset divestitures, implementing improvements in cultivation and manufacturing quality and efficiency, and optimizing our liquidity position, will provide a pathway to free cash flow generation in 2023. We are confident in the embedded growth in our strategic footprint and in the expected impact of the improvements we are making to influence our profitability, cash flow and liquidity position.”
Full Year 2022 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items):
| Year Ended Dec 31, | ||||||||||||
| 2022 | 2021 | % YoY | ||||||||||
| Revenue |
$ | 511,578 | $ | 460,080 | 11.2 | % | ||||||
| Gross Profit |
$ | 201,211 | $ | 194,015 | 3.7 | % | ||||||
| Adj. Gross Profit[1,2] |
$ | 216,657 | $ | 201,678 | 7.4 | % | ||||||
| Adj. Gross Margin[1,2] |
42.4 | % | 43.8 | % | -148 bps | |||||||
| Adj. EBITDA[1,2] |
$ | 67,376 | $ | 57,852 | 16.5 | % | ||||||
Fourth Quarter 2022 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items):
| Q4 2022 | Q3 2022 | Q4 2021 | % QoQ | % YoY | ||||||||||||||||
| Revenue |
$ | 126,187 | $ | 132,733 | $ | 139,276 | -4.9 | % | -9.4 | % | ||||||||||
| Gross Profit |
$ | 41,601 | $ | 52,113 | $ | 57,253 | -20.2 | % | -27.3 | % | ||||||||||
| Adj. Gross Profit[1,2] |
$ | 47,182 | $ | 56,870 | $ | 61,995 | -17.0 | % | -23.9 | % | ||||||||||
| Adj. Gross Margin[1,2] |
37.4 | % | 42.8 | % | 44.5 | % | -546 bps | -712 bps | ||||||||||||
| Adj. EBITDA[1,2] |
$ | 17,405 | $ | 20,993 | $ | 20,587 | -17.1 | % | -15.5 | % | ||||||||||
| [1] | Denotes a Non-GAAP measure. See “Non-GAAP Financial Measures” in this press release for more information regarding the Company’s use of non-GAAP financial measures, as well as Table 4 for reconciliation, where applicable. |
| [2] | Excludes $5.6 million in Q4 2022, $4.8 million in Q3 2022, and $4.7 million in Q4 2021; see the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 for additional disclosure. |
Top 5 Markets by Revenue in Q4[3]: California, Colorado, New Jersey, Ohio, Virginia
Top 5 Markets by Adjusted EBITDA in Q4[3]: Massachusetts, New Jersey, Ohio, Pennsylvania, Virginia
| [3] | Markets are listed alphabetically |
Operational Highlights
Enhancing scale and optimizing best-in-class retail network:
| • | Opened two Cannabist retail locations in Virginia (Carytown & Williamsburg) at the end of Q4 2022, and closed 1 unprofitable retail location (CO) in December 2022, ending the year with 84 active dispensaries |
| • | As part of ongoing efficiency initiatives to enhance profitability announced in January 2023, the Company closed 3 additional unprofitable locations (2 in Colorado, 1 in California) and subsequently signed a definitive agreement to divest 1 unprofitable location in Missouri |
| • | Also in Q1 2023, Company has opened 2 locations in Virginia (Hampton & Colonial Heights), bringing the current active retail location count to 83 |
| • | Retail revenue remained flat in Q4 2022, with a slight improvement in same store sales, in spite of pricing headwinds; wholesale revenue declined 30% sequentially due to pricing pressure and intentional inventory management, which negatively impacted Q4 gross margin |
| • | Company’s two active New Jersey retail locations were among the top dispensaries in the portfolio; the third New Jersey retail location is in development |
| • | Virginia topline revenue grew nearly 100% YoY, as new retail locations were added and the patient population continues to grow; Adj. EBITDA Margin for the year increased 19 percentage points over 2021 |
| • | Additional dispensaries in development include 4 in Virginia (scheduled to open in 2023), 1 in West Virginia (expected to open this week), 1 in New Jersey (expected to open in 2H 2023), and 1 currently in pursuit in Maryland |
Proven cultivation expertise and execution:
| • | In Q4 2022, the weighted average production cost per pound decreased by 8% across the portfolio |
| • | Enhanced production capabilities supported a shift in retail revenue product mix to include more concentrates, evidenced by a 5-percentage point increase in Q4 2022 |
| • | Continued progress on optimization of production planning, genetics selection, environmental controls and plant management across the cultivation portfolio |
| • | Cultivation efficiency and standardization across markets continued to improve over prior performance, with multiple states seeing improved potency TAC% through strict adherence to standard operating procedures |
Sustained momentum on branding initiatives at retail and product levels:
| • | In October 2022, launched Hedy, a new cannabis-infused edibles brand, in six markets and in a variety of form factors and flavors; Hedy was developed using insights from our unique technological platforms, such as Forage, that help us better understand what our customers are seeking; Hedy is now available in Arizona, Colorado, Delaware, Illinois, Massachusetts, Missouri, New York, and Virginia |
| • | During Q4 2022, saw continued growth of Stash Cash, the loyalty program and mobile application that launched in 14 markets in Q3 2022; Stash Cash provides Company with enhanced opportunity to engage and retain customers and patients, as well as insight into customer behaviors and preferences |
| • | In Q1 2023, launched new line of formulated cannabis tablets, Press 2.0, in Delaware, Massachusetts, New Jersey, Virginia and West Virginia |
| • | In-house brands accounted for 61% of all flower sold at Columbia Care dispensaries in Q4 2022 and 66% in FY 2022 |
| • | There are now 33 Cannabist locations in the U.S. with 5 additional openings planned in 2023 |
Capital Markets & Liquidity Highlights
| • | The Company generated $5.2 million of positive cash flow from operations in Q4 2022 and exited the year with $48.2 million in cash; Company spent approximately $1.9 million of cash in Q4 as a result of cost-savings, low CAPEX and improved working capital management, compared to $31.4 million of cash spend in Q3 2022 – a sequential improvement of $29.5 million |
| • | Capital expenditures in Q4 were approximately $3.4 million and $73.8 million for 2022 |
| • | On March 13, 2023, Company signed definitive agreement to divest interests in the Missouri market for approximately $7 million; Missouri market generated $1 million in EBITDA loss in 2022 |
| • | On March 28, 2023, Company exercised its unilateral right to extend the maturity date of its 13% senior secured notes in the amount of $38.2 million, originally due May 14, 2023, to May 14, 2024; Company has no debt maturities prior to that date other than approximately $5.6 million convertible note in December 2023 |
| • | The corporate restructuring initiatives announced in January 2023, which reduced or exited cultivation operations in 6 markets, closed 4 unprofitable retail stores in Colorado and California, and eliminated approximately 25% of our corporate positions, are expected to generate a net $35 million in annualized savings |
| • | Company has exited several markets and assets that were not accretive to positive cash flow, including closing its CBD and European business and selling its assets in Puerto Rico, which when combined with recent exit of Missouri, will generate an incremental savings of approximately $3 million annually going forward |
Conference Call and Webcast Details
The Company will host a conference call on Wednesday, March 29, 2023 at 8:00 a.m. ET to discuss financial and operating results for the fourth quarter and full year of 2022.
To access the live conference call via telephone, participants must pre-register at https://register.vevent.com/register/BIe13a43cb0fb742c3b2fd08064bace8a8. After registering, instructions will be shared on how to join the call for those who wish to dial in. A live audio webcast of the call will also be available in the Investor Relations section of the Company’s website at https://investors.columbia.care/ or at https://edge.media-server.com/mmc/p/9ed8sm24.
A replay of the audio webcast will be available in the Investor Relations section of the Company’s website approximately 2 hours after completion of the call and will be archived for 30 days.
About Columbia Care
Columbia Care is one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products and related services, with licenses in 16 U.S. jurisdictions. Columbia Care operates 126 facilities including 94 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information on Columbia Care, please visit www.columbia.care.
Non-GAAP Financial Measures
In this press release, Columbia Care refers to certain non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit and Adjusted Gross Margin. Columbia Care considers certain non-GAAP measures to be meaningful indicators of the performance of its business. These measures are not recognized measures under GAAP, do not have a standardized meaning prescribed by GAAP and may not be comparable to (and may be calculated differently by) other companies that present similar measures. Accordingly, these measures should not be considered in isolation from nor as a substitute for our financial information reported under GAAP. These non-GAAP measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our business that may not otherwise be apparent when relying solely on GAAP measures. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. We also recognize that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of companies within our industry.
With respect to non-GAAP financial measures, the Company defines EBITDA as net income (loss) before (i) depreciation and amortization; (ii) income taxes; and (iii) interest expense and debt amortization. Adjusted EBITDA is defined as EBITDA before (i) share-based compensation expense; (ii) goodwill and intangible impairment, (iii) adjustments for acquisition and other non-core costs; (iv) gain on remeasurement of contingent consideration, net, (v) fair value changes on derivative liabilities; and (vi) fair value mark-up for acquired inventory. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue. Adjusted Gross Profit is defined as gross profit before the fair mark-up for acquired inventory. Adjusted Gross Margin is defined as gross margin before the fair mark-up for acquired inventory.
The Company views these non-GAAP financial measures as a means to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the Company’s business. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.
Reconciliations of non-GAAP financial measures to their nearest comparable GAAP measures are included in this press release and a further discussion of some of these items will be contained in our annual report on Form 10-K.
Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information or forward looking statements within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of the Company are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements in this press release include, among others, statements related to: expectations related to growth, cost management and financial numbers including free cash flow, the Cresco transaction, and ongoing business expectations.
The Company has made assumptions with regard to its ability to execute on initiatives, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. Forward-looking information involves numerous assumptions, including assumptions on the satisfaction of the conditions precedent to the closing of the Cresco transaction; the receipt of any necessary regulatory approvals in connection with the Cresco transaction; the impact of the Cresco transaction on the Company’s and Cresco’s current and future operations, financial condition and prospects; the value of the Cresco shares; the costs of the Cresco transaction and potential payment of a termination fee in connection with the Cresco transaction; the ability to successfully integrate with the operations of Cresco and realize the expected benefits of the Cresco transaction; the ability to sign and close divestiture transactions related to the Cresco transaction; access to public and private capital for buyers of assets being divested in relation to the Cresco transaction; the fact that marijuana remains illegal under federal law; the application of anti-money laundering laws and regulations to the Company; legal, regulatory or political change to the cannabis industry; access to the services of banks; access to public and private capital for
the Company or for Cresco; unfavorable publicity or consumer perception of the cannabis industry; expansion into the adult-use markets; the impact of laws, regulations and guidelines; the impact of Section 280E of the Internal Revenue Code; the impact of state laws pertaining to the cannabis industry; the Company’s reliance on key inputs, suppliers and skilled labor; the difficulty of forecasting the Company’s sales; constraints on marketing products; potential cyber-attacks and security breaches; net operating loss and other tax attribute limitations; the impact of changes in tax laws; the volatility of the market price of the common shares of the Company; reliance on management; litigation; future results and financial projections; the impact of global financial conditions and disease outbreaks; projected revenue and expected gross margins, capital allocation, EBITDA break even targets and other financial results; growth of the Company’s operations via expansion; expectations for the potential benefits of any transactions including the acquisition of Green Leaf Medical and Medicine Man; statements relating to the business and future activities of, and developments related to, the Company after the date of this press release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations that planned transactions (including the Cresco transaction) will be completed as previously announced; expectations regarding cultivation and manufacturing capacity; expectations regarding receipt of regulatory approvals; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.
Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended December 31, 2022, to be filed with the applicable securities regulatory authorities and as also described from time to time in other documents filed by the Company with U.S. and Canadian securities regulatory authorities.
The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. No undue reliance should be placed on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release. Columbia Care undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company’s forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
Lee Ann Evans
SVP, Capital Markets
ir@col-care.com
Media Contact
Lindsay Wilson
VP, Communications
+1.978.662.2038
media@col-care.com
TABLE 1 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in US $ thousands, except share and per share figures, unaudited)
| Three Months Ended December 31 | Year Ended December 31 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue |
$ | 126,187 | $ | 139,276 | $ | 511,578 | $ | 460,080 | ||||||||
| Cost of sales |
(84,518 | ) | (77,282 | ) | (310,163 | ) | (258,402 | ) | ||||||||
| Cost of sales related to business combination fair value adjustments to inventory |
(68 | ) | (4,741 | ) | (204 | ) | (7,663 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
41,601 | 57,253 | 201,211 | 194,015 | ||||||||||||
| Selling, general and administrative expenses |
(402,358 | ) | (142,098 | ) | (617,451 | ) | (304,380 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(360,757 | ) | (84,845 | ) | (416,240 | ) | (110,365 | ) | ||||||||
| Other income (expense), net |
22,618 | 30,952 | (16,454 | ) | (36,349 | ) | ||||||||||
| Income tax benefit (expense) |
37,122 | (770 | ) | 11,213 | (139 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
(301,017 | ) | (54,663 | ) | (421,481 | ) | (146,853 | ) | ||||||||
| Net income (loss) attributable to non-controlling interests |
(907 | ) | (1,388 | ) | (5,476 | ) | (3,756 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) attributable to Columbia Care shareholders |
$ | (300,110 | ) | $ | (53,275 | ) | $ | (416,005 | ) | $ | (143,097 | ) | ||||
| Weighted average common shares outstanding - basic and diluted |
400,467,851 | 370,786,916 | 392,571,102 | 338,754,694 | ||||||||||||
| Earnings per common share attributable to Columbia Care shareholders - basic and diluted |
$ | (0.75 | ) | $ | (0.14 | ) | $ | (1.06 | ) | $ | (0.42 | ) | ||||
TABLE 2 - CONDENSED CONSOLIDATED BALANCE SHEET (SELECT ITEMS)
(in US $ thousands, unaudited)
| Three Months Ended | ||||||||||||||||
| December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | |||||||||||||
| Cash |
$ | 48,154 | $ | 50,023 | $ | 81,440 $ | 168,424 | |||||||||
| Total current assets |
237,177 | 208,515 | 256,110 | 323,883 | ||||||||||||
| Property and equipment, net |
357,993 | 370,820 | 373,877 | 355,968 | ||||||||||||
| Right of use assets |
219,895 | 259,655 | 254,849 | 250,413 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total assets |
994,726 | 1,371,578 | 1,420,465 | 1,482,443 | ||||||||||||
| Total current liabilities |
203,118 | 178,015 | 138,499 | 222,835 | ||||||||||||
| Total liabilities |
787,823 | 870,701 | 892,496 | 952,743 | ||||||||||||
| Total equity |
206,903 | 500,877 | 527,969 | 529,700 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total liabilities and equity |
$ | 994,726 | $ | 1,371,578 | $ | 1,420,465 | $ | 1,482,443 | ||||||||
TABLE 3 - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in US $ thousands, unaudited)
| Three Months Ended | ||||||||||||||||
| December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | |||||||||||||
| Net cash provided by (used in) operating activities |
$ | 5,152 | $ | (16,770 | ) | $ | (71,961 | ) | $ | (27,822 | ) | |||||
| Net cash (used in) investment activities |
(3,369 | ) | (14,276 | ) | (28,127 | ) | (29,555 | ) | ||||||||
| Net cash provided by (used in) financing activities |
$ | (3,652 | ) | $ | (371 | ) | $ | 13,454 | $ | 144,253 | ||||||
TABLE 4 - RECONCILIATION OF US GAAP TO NON-GAAP MEASURES
(in US $ thousands, unaudited)
| Three Months Ended December 31 | Year Ended December 31 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net income (loss) |
$ | (301,017 | ) | $ | (54,663 | ) | $ | (421,481 | ) | $ | (146,853 | ) | ||||
| Income tax (benefit) expense |
(37,122 | ) | 770 | (11,213 | ) | 139 | ||||||||||
| Depreciation and amortization |
21,711 | 19,201 | 84,788 | 53,002 | ||||||||||||
| Net interest and debt amortization |
14,035 | 11,328 | 52,542 | 30,014 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA (Non-GAAP) |
$ | (302,393 | ) | $ | (23,364 | ) | $ | (295,364 | ) | $ | (63,698 | ) | ||||
| Share-based compensation |
$ | 7,281 | $ | 6,989 | $ | 27,930 | $ | 25,018 | ||||||||
| Goodwill and intangible impairment |
340,121 | 72,328 | 340,121 | 72,328 | ||||||||||||
| Adjustments for other acquisition and non-core costs |
10,310 | (57,163 | ) | 38,407 | 29,827 | |||||||||||
| Gain on remeasurement of contingent consideration, net |
(37,362 | ) | 23,582 | (37,362 | ) | — | ||||||||||
| Fair value changes on derivative liabilities |
(620 | ) | (6,526 | ) | (6,560 | ) | (13,286 | ) | ||||||||
| Fair value mark-up for acquired inventory |
68 | 4,741 | 204 | 7,663 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA (Non-GAAP) |
$ | 17,405 | $ | 20,587 | $ | 67,376 | $ | 57,852 | ||||||||
Exhibit 99.2 FOURTH QUARTER & FULL YEAR 2022 INVESTOR PRESENTATION NEO:CCHW | CSE:CCHW | OTCQX:CCHWF | FSE:3LP March 2023
2 DISCLAIMER AND FORWARD-LOOKING STATEMENTS Disclaimer Columbia Care Inc. (the “Company” or “Columbia Care”) derives a substantial portion of its revenues from the cannabis industry in certain U.S. states, which industry is illegal under U.S. federal Law. Columbia Care is directly involved in both the adult-use and medical cannabis industry in the states of Arizona, California, Colorado, Illinois, Massachusetts, Missouri and New Jersey, and in the medical cannabis industry in the states of Delaware, Florida, Maryland, New York, Ohio, Pennsylvania, the District of Columbia, Utah, Virginia, and West Virginia, which states have regulated such industries. The cultivation, processing, sale and use of cannabis are illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970 (the “CSA”). Under the CSA, the policies and regulations of the United States federal government and its agencies are that cannabis has no medical benefit and a range of activities, including cultivation and the personal use of cannabis, are prohibited. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply. Until 2018, the federal government provided guidance to federal law enforcement agencies and banking institutions through a series of United States Department of Justice (“DOJ”) memoranda. The most recent such memorandum was drafted by former Deputy Attorney General James Cole in 2013 (the “Cole Memo”). On January 4, 2018, former U.S. Attorney General Jeff Sessions issued a memorandum to U.S. district attorneys that rescinded previous guidance from the U.S. Department of Justice specific to cannabis enforcement in the United States, including the Cole Memo (as defined herein). The former Attorneys General who succeeded former Attorney General Sessions following his resignation did not provide a clear policy directive for the United States as it pertains to state-legal marijuana-related activities. President Joseph R. Biden was sworn in as the 46th President of the U.S. on January 20, 2021. President Biden nominated Merrick Garland to serve as Attorney General in his administration, and he was confirmed on March 10, 2021. It is not yet known whether the Department of Justice under President Biden and Attorney General Garland will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy. Attorney General Garland stated at a confirmation hearing before the United States Senate that “It does not seem to me a useful use of limited resources that we have, to be pursuing prosecutions in states that have legalized and that are regulating the use of marijuana, either medically or otherwise. I don’t think that’s a useful use.” Attorney General Garland reiterated this view at a Senate Appropriations subcommittee hearing on April 26, 2022. Nonetheless, there is no guarantee that state laws legalizing and regulating the sale and use of marijuana will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to marijuana (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform federal guidance, as had been established by the Cole Memo, enforcement priorities are determined by respective United States Attorneys. Columbia Care makes no medical or treatment claims about our products, implied or otherwise, and each patient or customer should consult their treating physician, explore all options, and discuss their personal health to determine whether he or she may be a potential candidate for medical marijuana or other cannabis-derived products. Our products have not been evaluated by the Food and Drug Administration (“FDA”). In addition, our products have not been approved by the FDA to diagnose, treat, cure, or prevent any disease. In addition, we have not conducted clinical trials for the use of our products. Any references to quality, consistency, efficacy and safety of our products are not intended to imply that such claims have been verified in clinical trials. Non-GAAP Financial Measures In this presentation, Columbia Care may refer to certain non-GAAP financial measures, including, without limitation, EBITDA, Adjusted EBITDA and Adjusted Gross Margin. These measures do not have any standardized meaning in accordance with U.S. GAAP and may not be comparable to similar measures presented by other companies. Columbia Care considers certain non-GAAP measures to be meaningful indicators of the performance of its business. A reconciliation of such non-GAAP financial measures to their nearest comparable GAAP measure is included in this presentation and a further discussion of some of these items is contained in the Company’s Form 10-K for the twelve months ended December 31, 2022. Cautionary Note Regarding Securities Laws This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Columbia Care, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Risk Factors For a detailed description of risk factors associated with Columbia Care, refer to the “Risk Factors” section in Columbia Care’s Form 10-K for the year ended December 31, 2022, which are available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.
3 DISCLAIMER AND FORWARD-LOOKING STATEMENTS Caution Concerning Forward-Looking Statements This presentation contains certain statements that constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of Columbia Care are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking information involves numerous assumptions, including assumptions on the satisfaction of the conditions precedent to the closing of the Cresco transaction; the receipt of any necessary regulatory approvals in connection with the Cresco transaction; the impact of the Cresco transaction on the Company’s current and future operations, financial condition and prospects; the value of the Cresco shares; the costs of the Cresco transaction and potential payment of a termination fee in connection with the Cresco transaction; the ability to successfully integrate with the operations of Cresco and realize the expected benefits of the Cresco transaction; the ability to sign and close divestiture transactions related to the Cresco transaction; access to public and private capital for buyers of assets being divested in relation to the Cresco transaction; the fact that marijuana remains illegal under federal law; the application of anti-money laundering laws and regulations to the Company; legal, regulatory or political change to the cannabis industry; access to the services of banks; access to public and private capital for the Company or Cresco; unfavorable publicity or consumer perception of the cannabis industry; expansion into the adult-use markets; the impact of laws, regulations and guidelines; the impact of Section 280E of the Internal Revenue Code; the impact of state laws pertaining to the cannabis industry; the Company’s reliance on key inputs, suppliers and skilled labor; the difficulty of forecasting the Company’s sales; constraints on marketing products; potential cyber-attacks and security breaches; net operating loss and other tax attribute limitations; the impact of changes in tax laws; the volatility of the market price of the Company’s common shares; reliance on management; litigation; future results and financial projections; and the impact of global financial conditions and disease outbreaks; as well as those risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended December 31, 2022, filed with the applicable securities regulatory authorities and described from time to time in other documents filed by the Company with U.S. and Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management's expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this presentation as well as statements regarding the Company's objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. No undue reliance should be placed on forward-looking statements contained in this presentation. Such forward-looking statements are made as of the date of this presentation. Columbia Care undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company's forward-looking statements are expressly qualified in their entirety by this cautionary statement. This presentation contains future-oriented financial information and financial outlook information (collectively, FOFI ) about Columbia Care’s revenue, gross margins and adjusted EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. FOFI contained in this document was approved by management as of the date of this document and was provided for the purpose of providing further information about Columbia Care’s future business operations. Columbia Care disclaims any intention or obligation to update or revise any FOFI contained in this document, whether because of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein.
4 4 COMPANY OVERVIEW Optimizing Scale, Improving Efficiency and Growing Profitability Across Strategic National Platform 32 16 94 US Cultivation & Jurisdictions in (1) US Retail Locations (1) US Manufacturing Facilities $35B+ +2M 150+ 2027 TAM in Licensed Sqft Cultivation & Acres Outdoor (2) (3) (3) US States Production Capacity Cultivation Capacity 42% $512M 11% FY 2022 Adj. Gross FY 2022 Revenue YoY Topline Revenue (4) Margin Growth 1) Pro forma facilities either open or under development. Does not include non-operational retail locations as of 3/23/2023 2) Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, company estimates 3) Total capacity under existing licenses - additional development may be required to achieve 4) Non-GAAP figure. See “Non-GAAP Financial Measures” on previous slides
5 5 VERTICAL INTEGRATION ON NATIONAL SCALE PENNSYLVANIA NEW YORK MASSACHUSETTS 1 3 2 8 1 3 Vertically Integrated UTAH COLORADO OHIO from Coast to Coast 1 5 26 1 5 NEW JERSEY 2 3 Wholesale Distribution in 15 Markets DELAWARE 2 3 MARYLAND 32 Cultivation and ILLINOIS WEST VIRGINIA 2 4 Manufacturing 1 2 1 5 Facilities WASHINGTON DC 2 1 CALIFORNIA ARIZONA FLORIDA 94 Retail Locations* (83 Active / 11 In Development) 2 6 2 2 4 14 VIRGINIA Locations in development in 2022: 12 2 VA - 4, WV - 1, NY - 4, NJ - 1, MD - 1 In Development Operational Wholesale Cultivation and Manufacturing Retail Locations * Open or under development; as of March 29, 2023; Pro forma facilities either open or under development. Does not include 4 non-operational retail locations as of 3/23/2023
6 6 ONE OF THE MOST STRATEGICALLY POSITIONED MSOs (1) Addressable market is >52% of the US population with significant upside potential (2) Columbia Care US Footprint Columbia Care Addressable Market Pursuit Activity Adult Use Anticipated Medical Only State Population (M) Est 2023 Sales (US$M) Est 2027 Sales (US$M) Status Licenses Adult Use & Medical Pursuit Activity California 41.3 Both Unlimited $ 4,978.5 $ 6,576.5 Florida 22.2 $ 2,563.5 $ 4,503.3 Medical Limited Illinois 12.7 $ 2,167.3 $ 2,632.7 Both Limited Massachusetts 7.0 Both Limited $ 1,799.3 $ 1,878.8 Colorado 6.3 $ 1,657.1 $ 1,833.8 Both Unlimited Arizona 7.3 Both Limited $ 1,290.6 $ 1,420.3 $35B+ (2) New York 20.1 $ 1,258.7 $ 5,000.0 Both Limited Projected 2027 TAM in Licensed US Pennsylvania 12.9 $ 1,204.9 $ 1,931.4 Medical Limited (2) States (2) New Jersey 9.1 Both Limited $ 1,121.6 $ 3,000.0 Ohio 11.7 $ 518.3 $ 1,604.0 Medical Limited Maryland 6.2 $ 479.9 $ 1,311.2 Both* Limited Utah 3.3 Medical Limited $ 161.2 $ 298.0 Conversion to Medical and Adult-Use Offers Significant Upside (2) Virginia 8.7 $ 121.6 $ 3,000.0 Both* Limited ▪ Columbia Care has experienced 3x-4x top-line revenue growth in states that West Virginia 1.8 $ 52.2 $ 83.7 Medical Limited have already converted from medical-only to medical and adult-use Washington DC 0.7 $ 50.8 $ 133.8 Medical Limited ▪ Adult-use sales launched in New Jersey (April 2022), in New York (January Delaware 1.0 $ 39.8 $ 149.2 Medical Limited 2023, but MSO participation is pending), and are expected in Maryland (July 2023) TOTAL 172.3 $ 19,465.3 $ 35,356.7 ▪ Columbia Care’s strategic footprint is well positioned for the anticipated *Legislation passed, enactment regulations and timeline pending conversion of additional markets 1) US Census Bureau, Company estimates, Gallup poll, as of Nov 2020 2) Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, company estimates
7 2022 BUSINESS HIGHLIGHTS Improving efficiencies and optimizing scale across strategic national portfolio Revenue +11% YoY; Adj. EBITDA +16.5% YoY, with 14 out of 17 markets EBITDA positive during Q4 1 2022 Year-end cash balance of $48.2M due to cost savings and working capital management; Company generated $5.2 million of positive cash flow 2 from operations in Q4 2022 Performance Improvement in cultivation efficiency with focus on potency and productivity; Multiple states seeing Highlights improved potency TAC % through strict adherence 3 to SOPs; 68 high potency strains (>26% TAC) identified throughout the portfolio Generated Revenue of $512 rd th Opened 3 and 4 Cannabist locations in Virginia; (1) million, 42% Adj. Gross Margin Launched Press 2.0 and additional new products (1)(2) (edibles, Live Rosin, Rosin carts) in multiple 4 and Adjusted EBITDA of $67 markets million Continued strength of retail share of internal brand sales; Columbia Care flower brands over 60% of 5 sales in own dispensaries 1) Adjusted EBITDA and Adjusted Gross Margin are non-GAAP figures 2) Excludes $5.6 million in Q4 2022, $4.8 million in Q3 2022, and $4.7 million in Q4 2021; see 10-K for additional disclosure
8 REVENUE AND RETAIL FOOTPRINT Ended 2022 with 84 retail locations, with 11 additional locations in development $160.0 100 95 $140.0 90 $120.0 84 84 84 84 85 79 $139 $100.0 $133 $126 $132 80 In Q4 2022, $130 75 Opened 2 new $110 $80.0 $123 75 Cannabist retail 73 $93 $82 locations Virginia 70 $60.0 69 and closed one 67 retail location in 65 $40.0 Colorado 60 $20.0 55 $0.0 50 Q4 2020Q1 2021Q2 2021Q3 2021Q4 2021Q1 2022Q2 2022Q3 2022Q4 2022 Note: For the first six months of 2021, revenue includes Ohio dispensary operations prior to close of the CannAscend transaction
9 PROFITABILITY TRENDS BY MARKET Profitability metrics throughout national portfolio Top 5 Markets by Revenue Top 5 Markets by Adj. Gross Margin Top 5 Markets by Adj. EBITDA Top 5 Markets by Adj. EBITDA Margin Q4 2022 Q4 2022 Q4 2022 Q4 2022 Massachusetts Delaware Delaware California 57% 50% 73% 43% Massachusetts New Jersey New Jersey Colorado Of Total Revenue for Average Q4 2022 Adj. Of Total Adj. EBITDA Average Q4 2022 Adj. Ohio New Jersey Ohio New Jersey Q4 2022 Gross Margin for Q4 2022 EBITDA Margin Ohio Pennsylvania Pennsylvania Ohio Virginia Virginia Virginia Virginia Note: Markets listed alphabetically Average Adj. Gross Margin* by Length of Market Operations Margin Improvement Highlights 67% 66%✓ Utah, Virginia, West Virginia – newest markets open <24 Months are ramping, with Virginia already a top 5 market by every measure as a medical market 54% ✓ New Jersey – adult-use ramping, 1 retail location under development and 50% 49% Vineland II cultivation site operationalized with production & manufacturing 46% 43% 41% 40% 42% 39% 37% ✓ Florida – continued scale & yield improvements, with yield per square foot +12% 35% 35% 37% since last quarter ✓ California – restructuring and wind-down of Downtown Los Angeles retail and cultivation assets ✓ Colorado – cultivation improvements to increase yields, quality and utilization of manufacturing capacity; introduction of in-house brands subsequent to quarter end Overall 24+ Months <24 Months Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 * Excludes changes in fair value of biological assets and inventory sold for all periods presented, as well as $4.8 million in Q3 2022 relating to a one-time write-off in Colorado to reduce outdoor capacity, $4.3 million in Q2 2022 related to inventory revaluation adjustments, and $5.6 million in Q4 2022, $4.8 million in Q3 2022, and $4.7 million in Q4 2021; see 10-K for additional disclosure
TBU - Add in NJ stats/language as catalysts 10 2023 GROWTH CATALYSTS 140,000 50 45% 42% 45 120,000 38% 40 117,506 27% 100,000 35 77,445 30 73,880 80,000 25 CapEx spend on purpose-built 60,000 20 Initial CAPEX investments continue to 42,885 infrastructure generates returns as 15 generate returns as infrastructure 40,000 markets come online and assets 10 comes online in operational markets, 20,000 begin to generate revenue. 5 driving improvements in gross margin. CAPEX needs declining as assets are 0 0 FY 2019 FY 2020 FY 2021 FY 2022 operational. $Th % CAPEX Adj. Gross Margin* % * Excludes changes in fair value of biological assets and inventory sold for all periods presented, as well as $4.8 million in Q3 2022 relating to a one-time write-off in Colorado to reduce outdoor capacity, $4.3 million in Q2 2022 related to inventory revaluation adjustments, and $5.6 million in Q4 2022, $4.8 million in Q3 2022, and $4.7 million in Q4 2021; see 10-K for additional disclosure Multiple Catalysts Propelling Growth in 2023 Ramped cultivation & Expanded product offerings Optimization of canopy 4 additional retail locations to production capacity in ~1M with focus on CO2 and edibles capacity in Vineland & adding open in growing Virginia sqft greenhouse in New York & operational improvements 1 retail location in New Jersey medical program, in advance to be low-cost flower producer continued to drive growth and to support adult use market of adult use transition and wholesale supplier profitability in Florida Increased product offerings in Launched the state’s largest Expanded branded product Additional markets likely to several markets including wholesale operation and distribution and Cannabist transition to adult use, Ohio & Pennsylvania, with opened 4 retail locations, with retail network, expanded including Maryland in 2023, plans to introduce additional 1 additional in development in product distribution in where 1 additional dispensary high potency strains West Virginia wholesale channels is in development throughout the portfolio Steele, CO
11 11 EMBEDDED UPSIDE IN TRANSITIONING GROWTH MARKETS Columbia Care in New York Columbia Care in Maryland Columbia Care in Virginia $3B+ $5B+ $1B+ (1) (1) (1) Projected TAM Projected TAM Projected TAM 8 Retail Locations (4 Active, 4 In development) 12 Retail Locations (8 Active, 4 In Development) 4 Retail Locations (3 Active, 1 In Development) ~148k sqft Existing Cultivation & Production in ~147,765 sqft Existing Cultivation & Production Capacity ~59,040 sqft Existing Cultivation & Production Capacity Rochester and Phase 1 of Long Island greenhouse ~650k sqft Additional Cultivation & Production Capacity ~30k sqft Additional Cultivation & Production Capacity ~3k sqft Additional Cultivation & Production Capacity in Riverhead, NY; First Harvest Completed in Dec 2021 MARKET UPDATES MARKET UPDATES MARKET UPDATES • New regulations in effect July 1, 2022 removed the state registration • On March 31, 2021 Legislation (S.854-A/A.1248-A) was signed, • Legislation signed, legalizing adult-use cannabis. Sales expected to card process. Patients are able to bring written certifications directly legalizing adult-use cannabis and expanding medical marijuana; adult begin on July 1, 2023, allowing for legal possession of up to 1.5 to dispensary, which has facilitated a growth in patient registrations to use expected in 2023 and regulator communicated the intent for ounces of cannabis, pending house approval of legislative guidelines more than 45,000 medical companies to wholesale to initial social equity retailers • Under the new amendment, existing operators will pay a fee based • Adult-use sales awaiting final legislation with an official start date. • Access to the medical cannabis program has expanded; whole on the company’s current revenues to convert licenses from medical Legalizing possession and personal cultivation without providing for cannabis flower entered market in October 2021 to adult-use legal commerce is increasing pressure on lawmakers to work across • Columbia Care is among existing Registered Organizations that will • Legislation proposes the issuance of 120 retail licenses, 25 grower the aisle to put forth a plan for a retail market be able to operate up to 8 retail locations (5 medical + 3 co-located licenses and 25 processing licenses, growing the wholesale • Flower introduced to the medical market in September 2021 medical/adult-use) and remain vertically integrated opportunity in the state 1) Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, Company estimates
12 12 LOW-COST CULTIVATION, EFFICIENT & SCALABLE PRODUCTION 28 operational / in development facilities with +2 million sq. ft of cultivation and manufacturing capacity Jurisdiction Facility Count Total Size (sqft) Status Arizona 2 34,800 Operational California 1 45,572 Operational Colorado 3 108,227 Operational 20,000 Operational Delaware 2 37,524 Under development Florida 4 105,373 Operational Illinois 1 32,802 Operational Maryland 2 59,040 Operational Massachusetts 1 38,890 Operational New Jersey 2 320,724 Operational New York 2 798,346 Operational Ohio 2 117,722 Operational Pennsylvania 1 274,000 Operational Virginia 2 147,765 Operational Washington DC 2 16,591 Operational West Virginia 1 39,293 Operational (1) Total 28 2,196,219 1) Does not include 4 non-operational, Columbia Care licensed facilities
13 13 FINANCIAL HIGHLIGHTS (in US$ thousands) FY 2022A Q1 2022A Q2 2022A Q3 2022A Q4 2022A P&L / Cash Flow Revenue 511,578 123,087 129,571 132,733 126,187 Adj. EBITDA 67,377 16,832 12,029 20,993 17,523 Interest Expense 48,349 11,244 11,484 12,974 12,647 Capital Expenditure 73,887 29,511 29,162 11,851 3,363 Balance Sheet Cash 48,154 168,424 81,440 50,023 48,154 PP&E 357,993 355,968 373,877 370,820 357,993 Total Assets 1,086,066 1,482,443 1,420,465 1,371,578 1,086,066 Total Liabilities 850,716 952,743 892,496 870,701 850,716 Shareholder's Equity 235,350 529,700 527,969 500,877 235,350 Note: Results are reported in US GAAP
14 14 FOURTH QUARTER & FULL YEAR 2022 STATE HIGHLIGHTS Top 5 Markets by Q4 2022 Revenue: California, Colorado, New Jersey, Ohio, Virginia Top 5 Markets by Q4 2022 Adjusted EBITDA: Massachusetts, New Jersey, Ohio, Pennsylvania, Virginia Market Commentary • Average dispensary sales, average unit price and transactions increased from Q3 2022 • Driven by significant competitive pricing pressure for manufactured goods; bulk & packaged flower due to market saturation and economic California climate decreased wholesale pricing • Restructuring and wind down of DTLA dispensary and cultivation site in January to address oversupply of biomass in the market and illicit grows; outdoor and greenhouse material flooding the market at extremely low prices and driving the price down • Ongoing optimization of asset base in Colorado via restructuring and wind down of three cultivation sites in January to address oversupply of biomass; ceased operations at three unprofitable retail locations Colorado • QoQ decrease in sales due to competitive pricing, decreased average dispensary sales and decreased transactions • QoQ decrease in GM due to heavy promotional activity to clear out aged inventory and obsolesce packaging • Wholesale flower pricing continues to see price deterioration, especially for flower category • Strong automation and process throughout the manufacturing facility with good trend of KPIs Massachusetts • Launched new SKUs in 2022, including Shake 7g & 14gbags, Roll Your Own pre-roll kits, wax & batter, Triple 7 pre-rolls and popcorn, Seed & Strain popcorn, Tyson Bites, Press 2.0 • Revenue +150% in 2H 2022 due to adult-use sales and strong wholesale; GM and EBITDA trending positively as assets are optimized • Deptford and Vineland were among top 5 of all dispensaries in 2H 2022; one additional dispensary is in development New Jersey • Vineland II was approved in May 2022 and was fully populated in Q4; automation for flower and pre-rolls fully operational in the market • Multiple SKUs, brands, product line extensions and flavors were launched including Dablicators, Amber Hash, Tyson and pre-roll packs
15 15 FOURTH QUARTER & FULL YEAR 2022 STATE HIGHLIGHTS Top 5 Markets by Q4 2022 Revenue: California, Colorado, New Jersey, Ohio, Virginia Top 5 Markets by Q4 2022 Adjusted EBITDA: Massachusetts, New Jersey, Ohio, Pennsylvania, Virginia Market Commentary • Strain specific C02 carts and RSO Dablicators under the Seed & Strain brand introduced in Q4 provided more product diversity, which allowed us to increase internal sales Ohio • New operators set to open throughout 2023 will lead to initial increase in wholesale opportunities • Topline revenue grew 6% YoY in Ohio; annual Adj. EBITDA improved 40% over 2021 • Restructuring of the Saxton cultivation facility will allow us to reduce inventory, cut expenses and better position the facility for future adult-use market Pennsylvania • Retail revenue decreased due to price suppression, market saturation and new dispensaries coming online • Launched Classix and Triple 7 brands, enhancing product offerings in market • Revenue increased +97% YoY with the addition of new retail locations and a growing medical program (approx. 55,000 registered patients and counting) Virginia• Automated flower packaging has significantly increased throughput of flower production • In Q4, launched Press 2.0 tablets in high demand and preparing to launch 3 flavors of ODTs in early 2023 • Williamsburg dispensary opened in Q4 2022, the Company's 6th location; in Q1 2023, 2 additional locations have opened, with 4 in development
16 BRANDS Tempe, AZ
17 CANNABIST EXPERIENCE Columbia Care’s new retail storefront experience is centered on making shopping simple and approachable for the vast range of experience levels as cannabis use is normalized and legalized across the US, with knowledgeable staff and technology-enhanced interaction. 33 Cannabist Locations Open to Date • Tempe, AZ• Deptford, NJ• St. Albans, WV • San Diego, CA• All 14 FL locations• Morgantown, WV • Villa Park, IL• Virginia Beach, VA• Chicago, IL • Lowell, MA• Williamstown, WV• Vineland, NJ • Springville, UT• Beckley, WV• Portsmouth, VA • Boston, MA• Brooklyn, NY• Carytown, VA • Williamstown, VA Near-term Pipeline 1 West Virginia location; 2 Virginia locations; 1 New Jersey location Early Insights - Cannabist Rebrand Impact (1) Villa Park, IL Case Study • +15% increase in revenue • +19% increase in number of transactions • Top 3 all-time highest weekly sales occurred since rebrand 1) Comparison of first 7 full weeks of operation as Cannabist to prior 7 weeks of operation prior to rebrand
18 BUILDING NATIONAL BRAND AND PRODUCT PORTFOLIO Growing our proprietary brand footprint through expanded market penetration and wholesale reach In-house brands accounted for over 65% of all flower sold at Columbia Care owned dispensaries in FY 2022. Owned brands also made up ~50% of sales in FY 2022 Wholesale SKU distribution available in 15 markets in 2022 Columbia Care house brands are currently available in all 16 of its operational markets Columbia Care currently has 55 different product categories across its house brands
19 19 AWARD-WINNING PRODUCTS & SERVICES High Times Cannabis Cup Illinois 2021 st • Hybrid Flower 1 Place: Triple 7, Rainbow Runtz nd • Indica Flower 2 Place: Seed & Strain, Velvet Glove nd • Pre-Roll 2 Place: Seed & Strain, Cherry Chem rd • Sativa Flower 3 Place: Triple 7, Tropical Runtz High Times Cannabis Cup California 2022 nd • Sativa Flower 2 Place: Triple 7, Super Boof rd • Indica Flower 3 Place: Triple 7, Pancakes #7 High Times Cannabis Cup Illinois 2022 rd • Pre-Roll 3 Place: Triple 7, Tropical Runtz Clio Cannabis Awards 2021 • Clio Cannabis Bronze Award: Forage, Digital/Mobile E-Commerce Category WEEDCon 2021 Harvest Cup • Best Flower - Hybrid: Triple 7, Peanut Butter Breath MarCom 2021 • Gold Award: Forage, Mobile Buying Experience Category • Platinum Award: Cannabist, Branding Refresh Category MarCom 2022 • Gold Award: Hedy, Marketing/Promotion Category • Platinum Award: Classix, Design (Print) Category Errl Cup 2023 st • Isolate Category 1 Place: Amber, Dat Flava Diamond Dust
20 ROOTED IN LAND & HARVESTED BY HAND We believe in the naturally restorative properties of cannabis and we proudly propagate that belief by sharing our bounty of flower with you. Upscale yet accessible, Seed & Strain is the most widely distributed brand across the entire portfolio. nd Seed & Strain is a 2021 High Times Award Winner, winning 2 Place in the Best Indica Flower category (Velvet Glove) and nd 2 place in the Best Pre-Roll category (Cherry Chem).
21 Our Cannabis is at the uppermost end of the quality spectrum, and our strains are unwavering in consistency. We’ve gone above and beyond the highest industry standards to cultivate the best strains that deliver every time. Our ultra-premium brand has national penetration and is now available in 11 markets. Triple Seven has won multiple awards in the Illinois High Times Cannabis st rd Cup, including 1 Place Hybrid Flower and 3 Place Sativa Flower, and the nd California High Times Cannabis Cup, including 2 place Sativa Flower and rd 3 Place Indica Flower.
22 AMPLIFY TODAY Classix is our every day, timeless lifestyle brand that celebrates incredible cannabis moments shared with friends. Now available in 14 markets, Classix successfully launched in 5 markets (AZ, MA, IL, DE, & NJ), and represented the single largest launch week for a brand in Columbia Care history totaling 12% of all sales on day 1, and 14% of all sales after the first week*. The launch of Classix also marked industry's widest multi- state flower brand launch in a single day. *Note: For markets in which the product is available
23 HEDY SLIDE Whichever path you choose, it’s always an exhilarating one. With HEDY the sky's the limit. Infused with Azuca fast-acting TiME INFUSION™, allowing high- quality cannabinoids to take effect in a groundbreaking, consistent, and predictable two to fifteen minutes. In Q3 2022, Hedy launched across six markets (AZ, CO, DE, MA, MO, VA), and expanded into two additional markets (IL and NY) in Q4 2022. Hedy is currently available in the following form-factors: gummies, chocolate drops, chocolate bar and effects-based gummies. We anticipate the launch of additional markets and form factors in 2023. Footer
24 TYSON IS BACK. Tyson 2.0 is an extraordinary balance of premium and affordable, full-spectrum cannabis flower, concentrates, and consumables available at retailers nationwide. Tyson 2.0 launched with Columbia Care as its exclusive national cultivation and manufacturing partner. Tyson 2.0 currently offers 3.5g flower, a 0.5g pre-roll and 28g flower and is sold through both our wholesale and retail channels. Tyson 2.0 launched in December 2021 and is currently available in 10 Columbia Care markets: AZ, CA, CO, DE, DC, MD, PA, IL, MA and OH.
25 Formulations crafted by connoisseurs Vibes crafted by you Our customers have nominated AMBER for San Diego’s Best Concentrate Product and Best Overall Concentrate Brand 2022. Additional products launched in multiple markets during Q4 2022, including AMBER Diamonds, Cured Crumble, Diamond Sauce, Live Resin and Shatter. AMBER is now available in 10 markets (AZ, CA, CO, DC, DE, IL, MA, NJ, PA, WV).
26 High potency and high quality aren’t mutually exclusive. Take control of your cannabis with hard pressed THC tablets formulated by industry experts for morning, day and night. The choice is yours. The pleasure is ours. PRESS 2.0 was created as a portable, convenient, and discreet option. Shine, Rally and Doze feature fast-acting cannabis and special formulations designed for morning, afternoon, and night routines. The new PRESS 2.0 hard-pressed tablets are now available in six markets (CA, DE, MA, NJ, VA, WV), with launches in additional states planned, pending regulatory approvals.
27 A RETAIL PLATFORM BUILT FOR CONTINUOUS INNOVATION How do you want to feel today? Technology and efficiency innovation will continue to heighten the in-store and at-home shopping experience at Cannabist and create an all-encompassing ecosystem from home to dispensary and online. Forage is our award-winning online cannabis discovery tool that matches strain and product recommendations to how you want to feel. We are the first cannabis company to bring a technology solution like this to the market that offers a truly unique consumer experience. Since the launch of Forage in June 2021, we have seen increased adoption on mobile and in the way the product is being leveraged in stores. We are continuing to explore opportunities around branded advertising and engaging content. Footnote
28 Stash Cash app offers a streamlined shopping experience to build and track loyalty rewards, shop from anywhere and discover new products. Stash Cash has features that allow Earn rewards for enjoying cannabis. The Stash Cash app is a platform for users to set their favorite dispensary and It doesn’t get any simpler than that. customers to build loyalty rewards, shop shop, earn and redeem points for Build your stash, save your cash from anywhere and discover new purchases made, discover new products products using Forage, connect via social media CANNABIS REWARDED and much more Footer
Footer